Fool.com
Growing the love for stocks
Results 61 - 70 of 299 : Previous 3 4 5 6 7 8 9 10 11 Next
The Best Parking Spots for Long-Term Savings
Making sense of the retirement account mumbo jumbo.
Schering and Merck: A Match Made in Purgatory
Merck needs Schering, and Schering has to sit there and take it.
The Side Effects of Competition
It's often the competitors that determine how bad the side effects can be.
Bristol-Myers Squibb: On the Patent Cliff's Edge
The fall is still going to hurt.
Gilead: Helping Investors Cope With the Market
Diversifying seems to be paying off for the drugmaker.
Bristol-Myers and AstraZeneca will have to test their drug after it goes on the market.
A two-day FDA panel should get the blood (sugar) flowing.
Refreshing? Bad? Should those words really be in the same description?
The bigger they are, the harder they (might) fall.
More data from AstraZeneca's Jupiter study pops up.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK